Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
21 results
  • Lung Cancer, Colorectal Cancer, Pancreatic Cancer

25-110          Phase I

3263-001: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

  • Sarcoma, Thyroid Cancer, Lung Cancer, Kidney Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, Liver Cancer, Breast Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Sarcoma, Prostate Cancer, Colorectal Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Pancreatic Cancer

25-464          Phase I

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Endometrial Cancer, Lung Cancer

25-249          Phase I

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052666/SGN-MesoC2 in Participants with Advanced Solid Tumors

  • Esophageal Cancer, Gastric (Stomach) Cancer, Pancreatic Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Pancreatic Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Prostate Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

25-375          Phase I

A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS PI3Ka inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

  • Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Sarcoma, Pancreatic Cancer, Liver Cancer, Gastric (Stomach) Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

Showing 1 - 10 of 21 results